As evidenced by an article published by the United States National Cancer Institute (NCI) in January 2020, it seems increasingly likely that the next stage in vitamin C’s long journey towards the cancer mainstream will involve coupling it with conventional treatments such as chemotherapy. In what will clearly have been seen by the pharma industry as a major threat to its multibillion-dollar cancer drug business, the NCI article authors evaluated high-dose intravenous vitamin C therapy and concluded that “given the current high financial cost of new cancer drugs, it seems rational to improve the effectiveness of current therapies by studying their clinical interactions with vitamin C.” They predicted that “the implementation of this treatment paradigm could provide benefit to many cancer patients.”
Using high-dose vitamin C alongside conventional cancer treatments will ultimately only be a stepping-stone, however. Cutting-edge studies conducted at the Dr. Rath Research Institute have already demonstrated that combining vitamin C with a specific group of other micronutrients enables the blocking of all key mechanisms that make cancer a deadly disease. As described in the book ‘Victory Over Cancer’, authored by Dr. Rath and Dr. Aleksandra Niedzwiecki, this includes blocking the secretion of the collagen digesting enzymes produced by cancer cells, inhibiting the invasion and metastasis of cancer cells, blocking the growth of tumors and the formation of new blood vessels to feed them, as well as inducing the natural death of cancer cells.
To read about Dr. Rath’s Cellular Health recommendations for the prevention of cancer, see this article on our website.
Air is an Overlooked Source of Nutrients: Evidence Shows We Can Inhale Some Vitamins
December 6, 2024France Proposes Slashing Maximum Levels of Vitamins and Minerals in Supplements
December 6, 2024High-Dose IV Vitamin C Plus Chemotherapy Found to Double Survival Time in Advanced Pancreatic Cancer
News
Results from a randomized, phase 2 clinical trial show that adding high-dose, intravenous (IV) vitamin C to chemotherapy doubles the overall survival of patients with late-stage metastatic pancreatic cancer from eight months to 16 months.
[Source: medicalxpress.com]
[Image source: Adobe Stock]
Comment
As evidenced by an article published by the United States National Cancer Institute (NCI) in January 2020, it seems increasingly likely that the next stage in vitamin C’s long journey towards the cancer mainstream will involve coupling it with conventional treatments such as chemotherapy. In what will clearly have been seen by the pharma industry as a major threat to its multibillion-dollar cancer drug business, the NCI article authors evaluated high-dose intravenous vitamin C therapy and concluded that “given the current high financial cost of new cancer drugs, it seems rational to improve the effectiveness of current therapies by studying their clinical interactions with vitamin C.” They predicted that “the implementation of this treatment paradigm could provide benefit to many cancer patients.”
Using high-dose vitamin C alongside conventional cancer treatments will ultimately only be a stepping-stone, however. Cutting-edge studies conducted at the Dr. Rath Research Institute have already demonstrated that combining vitamin C with a specific group of other micronutrients enables the blocking of all key mechanisms that make cancer a deadly disease. As described in the book ‘Victory Over Cancer’, authored by Dr. Rath and Dr. Aleksandra Niedzwiecki, this includes blocking the secretion of the collagen digesting enzymes produced by cancer cells, inhibiting the invasion and metastasis of cancer cells, blocking the growth of tumors and the formation of new blood vessels to feed them, as well as inducing the natural death of cancer cells.
To read about Dr. Rath’s Cellular Health recommendations for the prevention of cancer, see this article on our website.
Dr. Rath Health Foundation
Related posts
Prenatal B12 Deficiency May Negatively Impact Child Speech and IQ
Read more